News und Analysen
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the following investor conferences:
-
Guggenheim
Quidel to Hold Fiscal Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 17th, 2022
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal fourth quarter and full year
Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that following a request from the U.S. Food and Drug Administration (FDA) the companies have initiated a rolling submission
Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that following a request from the U.S. Food and Drug Administration (FDA) the companies have initiated a rolling submission
Pulse Biosciences to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to
Pfizer Announces New Chief Development Officer
Pfizer Inc. (NYSE: PFE) today announced that William Pao, M.D., Ph.D., will join the Company as Executive Vice President and Chief Development Officer effective March 21, 2022. Dr. Pao will be a
Pfizer Announces New Chief Development Officer
Pfizer Inc. (NYSE: PFE) today announced that William Pao, M.D., Ph.D., will join the Company as Executive Vice President and Chief Development Officer effective March 21, 2022. Dr. Pao will be a
Waters Acquires Charge Detection Mass Spectrometry Technology to Broaden its Application in Cell and Gene Therapy
Waters Corporation (NYSE:WAT) today announced it has acquired the technology assets and intellectual property rights of Megadalton Solutions, Inc., an early-stage developer of Charge Detection Mass
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, February 8, 2022.
In connection with the
Premier, Inc. Reports Fiscal Year 2022 Second Quarter Results
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2022 second quarter ended December 31, 2021.
"Our
European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) granted marketing authorization for LORVIQUA® (lorlatinib, available in the U.S. under the brand name LORBRENA®) as
European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) granted marketing authorization for LORVIQUA® (lorlatinib, available in the U.S. under the brand name LORBRENA®) as
Gerresheimer AG: The leading supplier of injection vials Gerresheimer expands production in Wertheim
Gerresheimer AG: Der führende Anbieter von Injektionsfläschchen Gerresheimer erweitert Produktion in Wertheim
Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment
Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional
Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment
Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional
Agilent and A*STAR’s SIFBI Sign Research Collaboration Agreement to Advance Singapore Agri-Food Industry
Agilent Technologies Inc. (NYSE: A) recently signed a Research Collaboration Agreement (RCA) with the Singapore Institute of Food and Biotechnology Innovation (SIFBI) outlining their collaboration
NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand
Go365® by Humana Announces Winners of Fourth Annual National Step Challenge, Resulting in 7.2 Billion Steps Taken and One Million Meals Donated to Feeding America®
Today, leading health and well-being company, Humana Inc. (NYSE: HUM), announced the winners of its 2021 Go365 National Step Challenge – a health and wellness competition that focuses on improving
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine
DGAP-News: Evotec geht iPSC-basierte Forschungspartnerschaft mit Boehringer Ingelheim im Bereich Augenheilkunde ein
DGAP-News: Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology
Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, announced the presentation